Composition for preventing or treating periodontitis containing cannabidiol and taurine

Abstract

The present invention relates to a composition for preventing or treating periodontitis, which contains cannabidiol and taurine. The composition of the present invention can effectively prevent or treat periodontitis by inhibiting inflammatory factors and directly suppressing alveolar bone loss. Furthermore, the composition is safe for the human body and has few side effects, making it suitable for a variety of uses, such as as an ingredient in pharmaceuticals, quasi-drugs, or health functional foods.

Description

[Technical Field]

[0001] This application claims priority from Korean Patent Application No. 10-2022-0137558, filed on October 24, 2022, the entire specification of which is incorporated herein by reference.

[0002] The present invention relates to a composition for preventing or treating periodontitis, comprising cannabidiol and taurine. [Background technology]

[0003] Periodontitis is a chronic inflammatory disease characterized by the destruction of connective tissue and alveolar bone loss. The primary etiology of periodontal tissue destruction is a host immune response mediated by dental biofilms containing periodontal pathogens. For example, the Gram-negative anaerobic bacterium Porphyromonas gingivalis, one of the major pathogens of periodontitis, releases lipopolysaccharides (LPS) from outer membrane vesicles. LPS stimulates macrophages to secrete inflammatory mediators, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), cyclooxygenase (COX), inducible nitric oxide synthase (iNOS), and matrix metalloproteinases (MMPs). These molecules primarily act as potential mediators of alveolar bone resorption in periodontitis.

[0004] In periodontal research, ligature-induced periodontitis has been developed in animals. For example, rodent models have been widely used to investigate the mechanisms of periodontal disease. Ligation induces localized bacterial accumulation in the subgingival area, enhancing bacterial-mediated inflammation and bone loss.

[0005] Cannabidiol (CBD), a substance isolated and extracted from cannabis, is one of the main physiologically active compounds in cannabis, along with THC, and has been reported to be effective against a variety of diseases. In particular, CBD-related receptors have been reported to play an important role in bone formation, suggesting that CBD indirectly inhibits bone loss and bone formation. CBD also plays an important role in suppressing inflammation in rheumatoid arthritis synovial fibroblasts and inhibits key cytokines (e.g., IL-1b, TNF-α, iNOS, and Cox-2) involved in inflammation in periodontitis. However, there are currently no reports of CBD directly suppressing periodontal bone loss while simultaneously suppressing inflammation caused by dental disease.

[0006] On the other hand, taurine is known to have many physiological functions. For example, taurine is now known to be involved in osmoregulation, membrane stabilization, calcium mobilization, neurotransmission, reproduction, and detoxification. In particular, taurine has been reported to have anti-inflammatory effects and protect cells from the cytotoxic effects of inflammation. However, there are currently no reports of its therapeutic effect on periodontitis. Summary of the Invention [Problem to be solved by the invention]

[0007] The present invention provides a pharmaceutical composition for preventing or treating periodontitis, which comprises cannabidiol and taurine, or pharmaceutically acceptable salts thereof, as active ingredients.

[0008] The present invention also provides a quasi-drug composition for preventing or ameliorating periodontitis, which contains cannabidiol and taurine, or pharmaceutically acceptable salts thereof, as active ingredients.

[0009] The present invention also provides a food composition for preventing or ameliorating periodontitis, which comprises cannabidiol and taurine, or a pharmaceutically acceptable salt thereof, as active ingredients.

[0010] However, the technical problems that the present invention aims to achieve are not limited to the above problems, and other problems not mentioned will be clearly understood by those skilled in the art from the following description. [Means for solving the problem]

[0011] The present invention provides a pharmaceutical composition for preventing or treating periodontitis, which comprises cannabidiol and taurine, or pharmaceutically acceptable salts thereof, as active ingredients.

[0012] The cannabidiol is represented by the following chemical formula 1:

[0013] [ka]

[0014] The taurine is represented by the following chemical formula 2:

[0015] [ka]

[0016] The active ingredients can inhibit TNF-α and IL-1β.

[0017] Furthermore, the present invention provides a topical composition for preventing or ameliorating periodontitis, which contains cannabidiol and taurine, or pharmaceutically acceptable salts thereof, as active ingredients.

[0018] Furthermore, the present invention provides a food composition for preventing or ameliorating periodontitis, which contains cannabidiol and taurine, or pharmaceutically acceptable salts thereof, as active ingredients.

[0019] Furthermore, the present invention provides a method for preventing or treating periodontitis, which comprises administering or ingesting to an individual a composition containing cannabidiol and taurine, or pharmaceutically acceptable salts thereof, as active ingredients.

[0020] Furthermore, the present invention provides use of a composition comprising cannabidiol and taurine, or a pharmaceutically acceptable salt thereof, as active ingredients for the prevention or treatment of periodontitis. [Effects of the Invention]

[0021] The composition according to the present invention can effectively prevent or treat periodontitis by inhibiting inflammatory factors and directly suppressing alveolar bone loss. Furthermore, it is safe for the human body and has almost no side effects, and can be used in a variety of applications, such as as an ingredient in pharmaceuticals, quasi-drugs, or health functional foods. [Brief explanation of the drawings]

[0022] [Figure 1] FIG. 1 shows the results of evaluating the intracellular toxicity of candanibiol and taurine.

[0023] [Figure 2] FIG. 2 shows the analysis of the inhibitory effects of candanibiol and taurine, either alone or in combination, on the inflammatory factors iNOS and COX-2.

[0024] [Figure 3] FIG. 3 shows the results of analyzing the inhibitory effect of candanibiol and taurine, either alone or in combination, on the formation of TRAP-positive cells in macrophages (***, P<0.001).

[0025] [Figure 4] FIG. 4 shows the bone loss inhibitory effects of candanibiol and taurine, when used alone or in combination (***, P<0.001).

[0026] [Figure 5] FIG. 5 shows the analysis of the inhibitory effect of combined treatment with candanibiol and taurine on pocket depth caused by induced periodontitis (***, P<0.001).

[0027] [Figure 6]Figure 6 shows the inhibitory effect of combined treatment with candanibiol and taurine on alveolar bone loss induced by periodontitis (*, P<0.05; **, P<0.01; ***, P<0.001). DETAILED DESCRIPTION OF THE INVENTION

[0028] The present inventors have experimentally confirmed that the combined use of cannabidiol and taurine has a significantly superior preventive or therapeutic effect on periodontitis, and have completed the present invention.

[0029] The development of periodontitis treatment agents developed to date has focused on treating periodontitis by suppressing inflammation. However, since bone loss caused by inflammation in periodontitis is very difficult or impossible to recover from, prevention by suppressing inflammation is also important, but the agents must be developed in a way that minimizes the problem of alveolar bone loss.

[0030] The present invention can effectively treat periodontitis by suppressing inflammatory factors and directly inhibiting the loss of alveolar bone, and can be usefully utilized as an ingredient in pharmaceuticals, quasi-drugs, functional health foods, etc.

[0031] The present invention will be described in detail below.

[0032] The present invention provides a composition for preventing or treating (or ameliorating) periodontitis, which comprises cannabidiol and taurine, or pharmaceutically acceptable salts thereof, as active ingredients.

[0033] The active ingredients can inhibit inflammatory factors such as TNF-α and IL-1β.

[0034] The composition may be a pharmaceutical composition, a quasi-drug composition, a food composition, or a functional health food composition.

[0035] The composition may contain cannabidiol:taurine in a concentration ratio of 1:5-50.

[0036] Cannabidiol (CBD) is a plant cannabinoid discovered in 1940 and is one of 113 cannabinoids identified in the Cannabis genus. As of 2018, preliminary clinical studies of cannabidiol include studies on anxiety, cognitive, and movement disorders. In the United States, a cannabidiol drug called Epidiolex has been approved by the U.S. Food and Drug Administration for the treatment of brain metastatic disease.

[0037] The structure of cannabidiol is represented by the following chemical formula 1:

[0038] [ka]

[0039] Taurine is a sulfur-containing amine present in the cells and tissues of mammals, including humans, and is found primarily in seafood, particularly shellfish such as oysters and scallops, as well as squid, octopus, and the dark red meat of fish. Taurine is also known to be extremely safe, and one of its distinguishing features from other amino acids is that even when taken in excess, there have been no reports of reduced absorption, growth inhibition, or other side effects.

[0040] The structure of taurine is represented by the following chemical formula 2:

[0041] [ka]

[0042] The method for obtaining cannabidiol and taurine of the present invention is not particularly limited, and they may be isolated from natural products, chemically synthesized using known methods, or commercially available products may be used.

[0043] In the present invention, cannabidiol and taurine may include hydrates, derivatives, etc., as well as solvates and stereoisomers thereof, provided that they have the same efficacy.

[0044] As used herein, "prevention" refers to any action that delays the onset of periodontitis by administering the composition of the present invention, and "treatment" and "amelioration" refer to any action that improves or favorably changes the symptoms of periodontitis by administering the composition of the present invention.

[0045] In the present invention, the term "pharmaceutically acceptable salt" or "salt thereof" may refer to an acid addition salt formed with a free acid. Acid addition salts can be prepared by conventional methods, for example, by dissolving a compound in an excess of aqueous acid and precipitating the salt with a water-miscible organic solvent, such as methanol, ethanol, acetone, or acetonitrile. Alternatively, equimolar amounts of a compound and an acid or alcohol (e.g., glycol monomethyl ether) in water can be heated, and the mixture can then be evaporated to dryness, or the precipitated salt can be filtered by suction. The free acid can be an inorganic or organic acid. Non-limiting examples of inorganic acids include hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, and stannic acid, which can be used alone or in combination. The "pharmaceutically acceptable salt" or "salt thereof" may refer to an acid addition salt formed with a free acid. Acid addition salts can be prepared by conventional methods, for example, by dissolving a compound in an excess of aqueous acid and precipitating the salt with a water-miscible organic solvent, such as methanol, ethanol, acetone, or acetonitrile. It is also possible to heat equimolar amounts of the compound and an acid or alcohol (for example glycol monomethyl ether) in water, and then evaporate the mixture to dryness or filter off the precipitated salt with suction.

[0046] Unless otherwise specified, the salts of cannabidiol and taurine may include both salts of acidic and basic groups that may be present in the compounds of cannabidiol and taurine. For example, the salts of cannabidiol and taurine include sodium, calcium, and potassium salts of hydroxy groups, and other pharmaceutically acceptable salts of amino groups include hard bromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate), and p-toluenesulfonate (tosylate) salts, which can be prepared by methods known in the art.

[0047] Pharmaceutical composition containing cannabidiol and taurine, or pharmaceutically acceptable salts thereof, as active ingredients The compositions of the present invention can be prepared from pharmaceutical compositions.

[0048] When the composition of the present invention is prepared from a pharmaceutical composition, the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier.

[0049] According to a preferred embodiment of the present invention, the composition of the present invention may be a pharmaceutical composition comprising (a) a pharmaceutically effective amount of the cannabidiol and taurine of the present invention described above; and (b) a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically effective amount" refers to an amount sufficient to achieve the efficacy or activity of the cannabidiol and taurine described above.

[0050] Pharmaceutically acceptable carriers are commonly used and include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition to the above ingredients, the pharmaceutical composition of the present invention may further contain lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

[0051] The pharmaceutical compositions of the present invention can be administered orally or parenterally.

[0052] The appropriate dosage of the pharmaceutical composition of the present invention can be formulated in various ways depending on factors such as the formulation method, mode of administration, the patient's age, weight, sex, pathological condition, diet, administration time, administration route, excretion rate, and reaction sensitivity. The typical dosage of the pharmaceutical composition of the present invention is in the range of 0.001 to 100 mg / kg for adults. Administration may be once a day or in several divided doses. However, the scope of the present invention is not limited to the above dosage.

[0053] The pharmaceutical composition of the present invention can be prepared in unit dose form or in a multi-volume container by formulating it with pharmaceutically acceptable carriers and / or excipients by a method readily practiced by one of ordinary skill in the art to which the invention pertains. In this case, the formulation may be in the form of a solution, suspension, syrup or emulsion in an oily or aqueous medium, or in the form of an extract, powder, granule, tablet or capsule, and may further contain a dispersing agent or stabilizer.

[0054] Quasi-drug composition containing cannabidiol and taurine, or pharmaceutically acceptable salts thereof, as active ingredients The composition of the present invention can be provided as a quasi-drug composition.

[0055] The active ingredient may be added as is, or other ingredients commonly used in oral quasi-drug compositions may be added, such as abrasives, humectants, binders, foaming agents, sweeteners, preservatives, medicinal ingredients, flavoring agents, pigments, solvents, whitening agents, solubilizers, or pH adjusters. The amount of active ingredient to be mixed can be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment).

[0056] The quasi-drug composition can be prepared in any formulation commonly prepared in the art, for example, toothpaste, mouthwash, mouth cleaner, gum, candy, mouth spray, oral ointment, oral varnish, oral toothpaste, and gum massage cream, but is not limited to these.

[0057] As an example, when the quasi-drug composition of the present invention is a dentifrice formulation, it may contain humectants, abrasives, binders, foaming agents, flavoring agents, sweeteners, coloring agents, preservatives, medicinal ingredients, solvents, pH adjusters, etc.

[0058] Food composition containing cannabidiol and taurine, or pharmaceutically acceptable salts thereof, as active ingredients The composition of the present invention can be provided as a food composition or a functional health food composition. When the composition of the present invention is prepared as a food composition, the active ingredients include not only the cannabidiol and taurine mentioned above, but also ingredients commonly added during food production, such as proteins, carbohydrates, fats, nutrients, seasonings, and flavorings. Examples of the carbohydrates include monosaccharides, such as glucose; disaccharides, such as maltose, sucrose, and oligosaccharides; and polysaccharides, such as dextrin, common sugars, and sugar alcohols, such as xylitol, ethanol, and erythritol. Flavoring agents include natural flavoring agents [thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)] and synthetic flavoring agents (saccharin, aspartame, etc.). For example, when the food composition of the present invention is prepared as a drink, it may further contain, in addition to the natural product extract of the present invention, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, cephalopod extract, jujube extract, licorice extract, etc.

[0059] The food composition or health functional food composition can be formulated in the form of powder, granules, rings, tablets, or capsules, as well as in the form of a general food or beverage.

[0060] There is no particular limitation on the type of food, and examples of foods to which the substance can be added include meat, sausage, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, dairy products including gum and ice cream, various soups, drinking water, tea, drinks, alcoholic beverages, and vitamin complexes, and all foods in the sense of the word are included.

[0061] Generally, when producing a food or beverage, the active ingredient can be added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, per 100 parts by weight of the raw material. However, in the case of long-term intake for the purposes of health and hygiene or health regulation, the amount may be less than the above range, and since the present invention uses natural substances and there are no safety issues, an amount greater than the above range can also be used.

[0062] The present invention will be described in more detail below with reference to examples. It will be obvious to those skilled in the art that these examples are merely for the purpose of explaining the present invention in more detail, and that the scope of the present invention is not limited by these examples. [Example]

[0063] Cannabidiol (CBD) was synthesized using olivetol and camphor according to a known synthesis method (V. Vaillancourt and KF Albizati, 1992). Taurine was purchased from Sigma-Aldrich, Korea.

[0064] Example 1. Cytotoxicity evaluation The intracellular toxicity of CBD and taurine was evaluated using osteoclasts (Raw264.7 cells), an inflammatory cell type, and the results are shown in Figure 1. CBD showed no intracellular toxicity up to a concentration of 12 μM, and taurine showed no intracellular toxicity up to a concentration of 0.6 mM. Each titration concentration was evaluated using CBD (10 μM) and taurine (0.5 mM), followed by intracellular toxicity evaluation using combined treatment. The results confirmed that the combination of CBD and taurine showed no intracellular toxicity.

[0065] Example 2. Analysis of the inhibitory effect on inflammation-related factors The inhibitory effects of CBD and taurine on inflammation-related factors COX-2 and iNOS were examined. RAW264.7 macrophage cells were treated with the inflammation-inducing substance LPS, and the anti-inflammatory effects of CBD and taurine alone and in combination were analyzed. The analysis confirmed that the combined use of CBD and taurine significantly increased the inhibitory effects of iNOS and COX-2 (Figure 2).

[0066] Example 3. Analysis of bone loss inhibitory efficacy To confirm the inhibitory effect of CBD and taurine on bone loss due to periodontitis, the extent of RANKL-induced TRAP formation and bone loss was analyzed using pit formation area analysis.

[0067] Analysis of the degree of inhibition of TRAP-positive cell formation by RANKL during osteoclast differentiation revealed that treatment with CBD or taurine alone had very low inhibitory effect on TRAP-positive cell formation, whereas the combined use of CBD and taurine significantly inhibited TRAP-positive cell formation (Figure 3).

[0068] Furthermore, to confirm the bone loss inhibitory effects of CBD and taurine, we analyzed the extent to which RANKL-mediated bone loss inhibition in macrophages was suppressed. When CBD or taurine was administered alone, the inhibitory effect was either minimal or very low, but when CBD and taurine were used together, the inhibitory effect was significantly higher (Figure 4).

[0069] Therefore, when CBD and taurine are used together, it is found that the inhibitory effect on inflammatory factors and inflammatory periodontitis is very strong, and the inhibitory effect on alveolar bone loss caused by inflammation is also very strong.

[0070] Example 4: Analysis of the periodontitis inhibitory effect of combined administration of CBD and taurine using an animal model [Experimental Method] Preparation of rats for the study

[0071] Rats were purchased from Nara Biotech Pyeongtaek Plant (Gyeonggi-do, Korea), and 6-week-old Sprague-Dawley male rats (M / 6W, 180-200g) were used in the study. Animal experiments were conducted in accordance with the Institutional Animal Care and Use Committee (IACUC) guidelines of Chonbuk National University.

[0072] Stabilization Period During the stabilization period, rats were kept in an animal room with a temperature of 20-24°C, humidity of 50-60%, and a 12-hour day and night cycle. They were allowed to adapt to the experimental environment through free food and water intake for one week.

[0073] Induction of periodontitis 1) Preparation of periodontitis-inducing bacteria (P. gingivalis) The periodontitis-inducing bacteria (P. gingivalis) used was provided by the Korean Oral Microbial Resource Bank (PG 2797). The periodontitis-inducing bacteria were prepared by inoculating the culture medium with an anaerobic batch three weeks prior to the start of the experiment and culturing for three weeks. The periodontitis-inducing bacteria cultured for three weeks were used for the seven-day periodontitis induction test, using the turbidity of the culture medium and the growth of the bacteria inoculated on the culture plate with the naked eye.

[0074] 2) Induction of periodontitis Periodontitis was induced by ligation using a band (TP Orthodontics, Inc., Seoul, Korea) treated with periodontitis-inducing bacteria. The band suture was stored in a slurry containing periodontitis bacteria, allowing the periodontitis bacteria to be thoroughly mixed into the band before handling. The ligation band was then cut to an appropriate size and placed in front of the maxillary premolar of the mandibular quadrant to induce periodontitis. After three days, the loss of the ligation band was confirmed, and a new ligation band was inserted in the lost area, and periodontitis was induced for seven days.

[0075] dosage 1) Medication method Seven days after induction, the development of periodontitis was assessed using pocket depth, and the test substances were then orally administered daily for two weeks. To prevent interference during administration (test substances implanted in the mouth during intragastric administration and residues of each test substance remaining in the syringe), the substance implanted in the zone was removed during a pause during administration, and the syringe was rinsed 3-5 times with water before administration to remove any residue.

[0076] A total of 50 animals were used in the experiment, with 10 animals in each treatment group for a total of 50 animals in 5 treatment groups, with 10 animals in each treatment group. The control group was a healthy group in which no periodontitis was induced, and the vehicle group was a control group in which no medication was administered after periodontitis induction and only water was administered. Insadol (4.5mg / kg, Dongkook Pharmaceutical, Korea) was purchased commercially and used as a medication control, dissolved in water and administered. To examine the efficacy of CBD concentration in periodontitis in the low-dose CBD + taurine (L-CBD + taurine) and high-dose CBD + taurine (H-CBD + taurine) treatment groups, taurine (100 mg / kg, Sigma-Aldrich, Seoul, Korea) was dissolved in water and administered at concentrations of L-CBD (2 mg / kg) and H-CBD (20 mg / kg), respectively.

[0077] Pocket depth measurement Pocket depth was measured using a pocket depth probe. The periodontal inflammation inhibitory effect of administering the test substance after inducing periodontitis was measured using the pocket depth. Measurements were taken three times, on days 7, 14, and 21 after inducing periodontitis, to examine the periodontitis inhibitory effect.

[0078] Micro-CT analysis for measuring alveolar bone loss Aleveolar bone loss was measured using a high-resolution in vivo X-ray microtomograph (HR MicroCT) (Bruker MicroCT, Kontich, MA, USA) at the Chonbuk National University Joint Laboratory. After 20 days of periodontitis induction, the test substances were administered, and then sacrificed 21 days later. Right maxillary samples were collected and analyzed by MicroCT. Bone mineral density (BMD) was measured for each treatment device using two-dimensional measurement software (Bruker Dataviewer, USA).

[0079] [Experimental Results] Analysis of the suppressive effect of combined administration of CBD and taurine on periodontal pocket depth To examine the periodontitis-inhibiting effect of different concentrations of CBD and taurine when administered together, pocket depth was measured, and the results are shown in Figure 5. Measurements showed that the H-CBD + Taurine group had the greatest pocket depth suppression for 7 days, from day 7 to day 14, after periodontitis induction. The H-CBD + Taurine group also had the greatest pocket depth suppression on day 21 (***, P<0.001). Treatment with high concentrations of CBD demonstrated the greatest periodontitis-inhibiting efficacy, demonstrating a particularly high periodontitis-inhibiting effect compared to in-saddle treatment.

[0080] Analysis of the inhibitory effect of combined administration of CBD and taurine on alveolar bone loss due to periodontitis BMD was measured to examine the efficacy of combined CBD and taurine in inhibiting alveolar bone loss at different concentrations, and the results are shown in Figure 6. The H-CBD + taurine group demonstrated the greatest inhibition of periodontitis-induced BMD loss, confirming that combined administration of high concentrations of CBD and taurine had excellent periodontitis treatment efficacy (*, P < 0.05; **, P < 0.01; ***, P < 0.001).

[0081] [Manufacturing example] The following describes examples of pharmaceutical or food preparations containing the above-mentioned CBD and taurine as active ingredients according to the present invention, but the present invention is not limited to these examples and is merely provided for illustrative purposes. Using the above-mentioned active ingredients, pharmaceutical or food compositions of Preparation Examples 1 and 2 were prepared according to the following compositional components and composition ratios in a conventional manner.

[0082] [Production Example 1] Production of pharmaceutical composition <1-1> Manufacturing of powders CBD and taurine 20mg Lactose hydrate 100mg Talc 10mg The above ingredients were mixed and filled into an airtight cloth to prepare an acid agent.

[0083] <1-2> Tablet manufacturing CBD and taurine 10mg Cornstarch 100mg Lactose hydrate 100mg Magnesium stearate 2mg The above ingredients were mixed and then compressed into tablets according to a conventional tablet manufacturing method.

[0084] <1-3> Manufacturing of capsules CBD and taurine 10mg Microcrystalline cellulose 3mg Lactose hydrate 14.8mg Magnesium stearate 0.2mg The above ingredients were mixed and then filled into gelatin capsules according to a conventional capsule manufacturing method to produce capsules.

[0085] <1-4> Manufacturing of injections CBD and taurine 10mg Mannitol 180mg Sterile distilled water for injection 2974mg Sodium monohydrogen phosphate 26mg The above ingredients were mixed and then prepared according to a conventional manufacturing method for injections, with the above ingredient contents per ampoule (2 mL).

[0086] <1-5> Manufacturing of liquid medicines CBD and taurine 10mg Lee Seonghwadang 10mg Mannitol 5mg Appropriate amount of purified water A moderate amount of lemon zest

[0087] The above ingredients were dissolved in purified water according to the usual manufacturing method, and after adding an appropriate amount of lemon flavor, purified water was added to make a total of 100 mL, which was then sterilized and filled into a brown bottle to prepare a liquid formulation.

[0088] [Production Example 2] Production of functional health foods <2-1> Manufacturing of dietary supplements CBD and taurine 10mg Vitamin mixture dosage Vitamin A acetate 70μg Vitamin E 1.0mg Vitamin B1 0.13mg Vitamin B2 0.15mg Vitamin B6 0.5mg Vitamin B 12 0.2 μg Vitamin C 10mg Biotin 10μg Nicotinamide 1.7mg Folic acid 50μg Calcium pantothenate 0.5mg Mineral mixture (appropriate amount) Ferrous sulfate 1.75mg Zinc oxide 0.82mg Magnesium carbonate 25.3mg Monobasic potassium phosphate 15mg Dicalcium phosphate 55mg Potassium citrate 30mg Calcium carbonate 100mg Magnesium chloride 24.8mg

[0089] The composition ratio of the above vitamin and mineral mixture is a preferred embodiment in which ingredients relatively suitable for health foods are mixed together, but the mixing ratio can be freely modified and implemented without any problems. After mixing the above ingredients according to the usual health food manufacturing method, granules can be produced and used in the manufacture of health food compositions according to the usual method.

[0090] <2-2> Manufacturing of health drinks CBD and taurine 10mg Vitamin C 15g Vitamin E (powder) 100g Iron lactate 19.75g 3.5g zinc oxide Nicotinamide 3.5g Vitamin A 0.2g Vitamin B1 0.25g Vitamin B2 0.3g Appropriate amount of purified water

[0091] The above ingredients were mixed according to a conventional method for producing a health drink, and then the mixture was stirred and heated at 85°C for about 1 hour. The resulting solution was then filtered and placed in a sterilized 2L container, which was then sealed, sterilized, and stored in a refrigerator before being used to produce the health drink composition of the present invention.

[0092] The above composition ratio is a preferred example of a mixture of ingredients that are relatively suitable for beverages, but the blending ratio may be arbitrarily modified depending on regional and ethnic preferences, such as the demand class, demand country, and intended use.

[0093] The above description of the present invention is for illustrative purposes only, and those skilled in the art will understand that the present invention can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. Therefore, it should be understood that the above-described embodiments are illustrative in all respects and are not limiting.

Claims

1. A pharmaceutical composition for preventing or treating periodontitis, comprising cannabidiol and taurine, or pharmaceutically acceptable salts thereof, as active ingredients.

2. 2. The pharmaceutical composition for preventing or treating periodontitis according to claim 1, wherein the cannabidiol is represented by the following chemical formula 1: 【Chemical 1】

3. 2. The pharmaceutical composition for preventing or treating periodontitis according to claim 1, wherein the taurine is represented by the following chemical formula 2: 【Chemistry 2】

4. 2. The pharmaceutical composition for preventing or treating periodontitis according to claim 1, wherein the active ingredient inhibits TNF-α and IL-1β.

5. A quasi-drug composition for preventing or ameliorating periodontitis, comprising cannabidiol and taurine, or pharmaceutically acceptable salts thereof, as active ingredients.

6. A food composition for preventing or ameliorating periodontitis, comprising cannabidiol and taurine, or pharmaceutically acceptable salts thereof, as active ingredients.

7. A method for preventing or treating periodontitis, comprising administering or taking to an individual a composition containing cannabidiol and taurine, or pharmaceutically acceptable salts thereof, as active ingredients.

8. 1. Use of a composition comprising cannabidiol and taurine, or a pharmaceutically acceptable salt thereof, as active ingredients for the prevention or treatment of periodontitis.

Images